Unbiased biomarkers for the prediction of respiratory disease outcomes

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: Unbiased biomarkers for the prediction of respiratory disease outcomes
Project Number: CORDIS-203682
Project web address: Follow on CORDIS
Organization: Novartis Pharma Ag, Switzerland, Basel
Collaborators: University Of Southampton, GB
University Of Manchester, GB
University Of Nottingham, GB
Umea University, SE
University Of Bern, CH
Karolinska Institutet, SE
Centre National De La Recherche Scientifique (Cnrs), FR
Universiteit Gent, BE
Kobenhavns Universitet, DK
Università Cattolica Del Sacro Cuore, IT
Imperial College Of Science, Technology And Medicine, GB
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., DE
Università Degli Studi Di Catania, IT
Università Degli Studi Di Roma Tor Vergata, IT
Hvidovre Hospital, DK
Universitetet I Bergen, NO
F. Hoffmann - La Roche Ltd., CH
Pfizer Ltd, GB
Glaxosmithkline Research And Development Limited, GB
Uniwersytet Jagiellonski, PL
Philips Electronics Nederland B.V., NL
Astra Zeneca Ab, SE
Chiesi Farmaceutici Spa, IT
Semmelweis Egyetem, HU
European Respiratory Society, CH
Universite D'Aix Marseille, FR
Ucb Biopharma Sprl, BE
Amgen Nv, BE
Boehriger Ingelheim International Gmbh, DE
Laboratorios Almirall S.A., ES
Netherlands Asthma Foundation, NL
Asthma Uk Lbg, GB
Merck Sharp And Dohme, Corp., US
International Primary Care Respiratory Group, GB
Lega Ltaliana Anti Fumo, IT
European Federation Of Asthma &Allergy Associations Ideell Forening, BE
Synairgen Research Ltd., GB
Biosci Consulting, BE
Janssen Biologics Bv, NL
Aerocrine Aktiebolag, SE
 
Project Description:
RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this bottleneck results from: a lack of useful and validated biomarkers, underperforming pre-clinical models, inadequate and incomplete sub-phenotyping, and insufficient disease understanding.HypothesisThe use of biomarker profiles comprised of various types of high-dimensional data, integrated with an innovative systems biology approach into distinct phenotype handprints, will enable significantly better prediction of therapeutic efficacy than single or even clustered biomarkers of one data type and will identify novel targets.StrategyU-BIOPRED proposes a staged-strategy:I)Generating an international consensus on diagnostic criteria for severe asthma.II)Unbiased discovery of sub-phenotypes of severe asthma in adult and paediatric patient cohorts using biomarker profiles (“fingerprints”) and systems biology to define “phenotype/handprints”.III)Validating the handprints for exacerbations, disease progression, and experimental challenges.IV)Using the handprints to improve human/animal in vivo and ex vivo models.V)Establishing the responsiveness and predictability of the handprints in gold standard and experimental therapeutic interventions.VI)Refinement of the diagnostic criteria and definition of severe asthma sub-phenotypes by incorporating the handprints, thereby enabling more focused drug development and faster delivery proof of concept for novel drugs.VII)Education, training and dissemination through a stakeholder platform and academic-industrial exchange, with potential for further growth as appropriate.Innovative approachWe will use a novel systems biology approach to integrate high dimensional data from invasive, non-invasive and patient-reported outcomes. All studies will include academic and EFPIA partners as active contributors.
 
Project Terms:
There are no related terms in database.
Project Title: Unbiased biomarkers for the prediction of respiratory disease outcomes
Project Number: CORDIS-203682
Project web address: Follow on CORDIS
Organization: Novartis Pharma Ag, Switzerland, Basel
Collaborators: University Of Southampton, GB
University Of Manchester, GB
University Of Nottingham, GB
Umea University, SE
University Of Bern, CH
Karolinska Institutet, SE
Centre National De La Recherche Scientifique (Cnrs), FR
Universiteit Gent, BE
Kobenhavns Universitet, DK
Università Cattolica Del Sacro Cuore, IT
Imperial College Of Science, Technology And Medicine, GB
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., DE
Università Degli Studi Di Catania, IT
Università Degli Studi Di Roma Tor Vergata, IT
Hvidovre Hospital, DK
Universitetet I Bergen, NO
F. Hoffmann - La Roche Ltd., CH
Pfizer Ltd, GB
Glaxosmithkline Research And Development Limited, GB
Uniwersytet Jagiellonski, PL
Philips Electronics Nederland B.V., NL
Astra Zeneca Ab, SE
Chiesi Farmaceutici Spa, IT
Semmelweis Egyetem, HU
European Respiratory Society, CH
Universite D'Aix Marseille, FR
Ucb Biopharma Sprl, BE
Amgen Nv, BE
Boehriger Ingelheim International Gmbh, DE
Laboratorios Almirall S.A., ES
Netherlands Asthma Foundation, NL
Asthma Uk Lbg, GB
Merck Sharp And Dohme, Corp., US
International Primary Care Respiratory Group, GB
Lega Ltaliana Anti Fumo, IT
European Federation Of Asthma &Allergy Associations Ideell Forening, BE
Synairgen Research Ltd., GB
Biosci Consulting, BE
Janssen Biologics Bv, NL
Aerocrine Aktiebolag, SE
 
Project Categories:
Natural Sciences > Aging-related markers and targets > Biomarkers of diseases
 
Other Information:
Fiscal Year: 2009
Project Start Date: 1 October 2009
Project End Date: 30 September 2015
Project program: FP7-JTI
 
Project Funding Information:
Funding Mechanism: JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)
Year Funding Organization Total Funding, $
2009 European Research Council $28,284,291
Project Title: Unbiased biomarkers for the prediction of respiratory disease outcomes
Project Number: CORDIS-203682
Project web address: Follow on CORDIS
Organization: Novartis Pharma Ag, Switzerland, Basel
Collaborators: University Of Southampton, GB
University Of Manchester, GB
University Of Nottingham, GB
Umea University, SE
University Of Bern, CH
Karolinska Institutet, SE
Centre National De La Recherche Scientifique (Cnrs), FR
Universiteit Gent, BE
Kobenhavns Universitet, DK
Università Cattolica Del Sacro Cuore, IT
Imperial College Of Science, Technology And Medicine, GB
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., DE
Università Degli Studi Di Catania, IT
Università Degli Studi Di Roma Tor Vergata, IT
Hvidovre Hospital, DK
Universitetet I Bergen, NO
F. Hoffmann - La Roche Ltd., CH
Pfizer Ltd, GB
Glaxosmithkline Research And Development Limited, GB
Uniwersytet Jagiellonski, PL
Philips Electronics Nederland B.V., NL
Astra Zeneca Ab, SE
Chiesi Farmaceutici Spa, IT
Semmelweis Egyetem, HU
European Respiratory Society, CH
Universite D'Aix Marseille, FR
Ucb Biopharma Sprl, BE
Amgen Nv, BE
Boehriger Ingelheim International Gmbh, DE
Laboratorios Almirall S.A., ES
Netherlands Asthma Foundation, NL
Asthma Uk Lbg, GB
Merck Sharp And Dohme, Corp., US
International Primary Care Respiratory Group, GB
Lega Ltaliana Anti Fumo, IT
European Federation Of Asthma &Allergy Associations Ideell Forening, BE
Synairgen Research Ltd., GB
Biosci Consulting, BE
Janssen Biologics Bv, NL
Aerocrine Aktiebolag, SE
 
Title FY Funding
There are no results for this project in database.
Project Title: Unbiased biomarkers for the prediction of respiratory disease outcomes
Project Number: CORDIS-203682
Project web address: Follow on CORDIS
Organization: Novartis Pharma Ag, Switzerland, Basel
Collaborators: University Of Southampton, GB
University Of Manchester, GB
University Of Nottingham, GB
Umea University, SE
University Of Bern, CH
Karolinska Institutet, SE
Centre National De La Recherche Scientifique (Cnrs), FR
Universiteit Gent, BE
Kobenhavns Universitet, DK
Università Cattolica Del Sacro Cuore, IT
Imperial College Of Science, Technology And Medicine, GB
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., DE
Università Degli Studi Di Catania, IT
Università Degli Studi Di Roma Tor Vergata, IT
Hvidovre Hospital, DK
Universitetet I Bergen, NO
F. Hoffmann - La Roche Ltd., CH
Pfizer Ltd, GB
Glaxosmithkline Research And Development Limited, GB
Uniwersytet Jagiellonski, PL
Philips Electronics Nederland B.V., NL
Astra Zeneca Ab, SE
Chiesi Farmaceutici Spa, IT
Semmelweis Egyetem, HU
European Respiratory Society, CH
Universite D'Aix Marseille, FR
Ucb Biopharma Sprl, BE
Amgen Nv, BE
Boehriger Ingelheim International Gmbh, DE
Laboratorios Almirall S.A., ES
Netherlands Asthma Foundation, NL
Asthma Uk Lbg, GB
Merck Sharp And Dohme, Corp., US
International Primary Care Respiratory Group, GB
Lega Ltaliana Anti Fumo, IT
European Federation Of Asthma &Allergy Associations Ideell Forening, BE
Synairgen Research Ltd., GB
Biosci Consulting, BE
Janssen Biologics Bv, NL
Aerocrine Aktiebolag, SE
 
Project Title Organization FY Funding
Project Title: Unbiased biomarkers for the prediction of respiratory disease outcomes
Project Number: CORDIS-203682
Project web address: Follow on CORDIS
Organization: Novartis Pharma Ag, Switzerland, Basel
Collaborators: University Of Southampton, GB
University Of Manchester, GB
University Of Nottingham, GB
Umea University, SE
University Of Bern, CH
Karolinska Institutet, SE
Centre National De La Recherche Scientifique (Cnrs), FR
Universiteit Gent, BE
Kobenhavns Universitet, DK
Università Cattolica Del Sacro Cuore, IT
Imperial College Of Science, Technology And Medicine, GB
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., DE
Università Degli Studi Di Catania, IT
Università Degli Studi Di Roma Tor Vergata, IT
Hvidovre Hospital, DK
Universitetet I Bergen, NO
F. Hoffmann - La Roche Ltd., CH
Pfizer Ltd, GB
Glaxosmithkline Research And Development Limited, GB
Uniwersytet Jagiellonski, PL
Philips Electronics Nederland B.V., NL
Astra Zeneca Ab, SE
Chiesi Farmaceutici Spa, IT
Semmelweis Egyetem, HU
European Respiratory Society, CH
Universite D'Aix Marseille, FR
Ucb Biopharma Sprl, BE
Amgen Nv, BE
Boehriger Ingelheim International Gmbh, DE
Laboratorios Almirall S.A., ES
Netherlands Asthma Foundation, NL
Asthma Uk Lbg, GB
Merck Sharp And Dohme, Corp., US
International Primary Care Respiratory Group, GB
Lega Ltaliana Anti Fumo, IT
European Federation Of Asthma &Allergy Associations Ideell Forening, BE
Synairgen Research Ltd., GB
Biosci Consulting, BE
Janssen Biologics Bv, NL
Aerocrine Aktiebolag, SE
 
Project number Project title Principal investigator
There are no any related projects.
Project Title: Unbiased biomarkers for the prediction of respiratory disease outcomes
Project Number: CORDIS-203682
Project web address: Follow on CORDIS
Organization: Novartis Pharma Ag, Switzerland, Basel
Collaborators: University Of Southampton, GB
University Of Manchester, GB
University Of Nottingham, GB
Umea University, SE
University Of Bern, CH
Karolinska Institutet, SE
Centre National De La Recherche Scientifique (Cnrs), FR
Universiteit Gent, BE
Kobenhavns Universitet, DK
Università Cattolica Del Sacro Cuore, IT
Imperial College Of Science, Technology And Medicine, GB
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., DE
Università Degli Studi Di Catania, IT
Università Degli Studi Di Roma Tor Vergata, IT
Hvidovre Hospital, DK
Universitetet I Bergen, NO
F. Hoffmann - La Roche Ltd., CH
Pfizer Ltd, GB
Glaxosmithkline Research And Development Limited, GB
Uniwersytet Jagiellonski, PL
Philips Electronics Nederland B.V., NL
Astra Zeneca Ab, SE
Chiesi Farmaceutici Spa, IT
Semmelweis Egyetem, HU
European Respiratory Society, CH
Universite D'Aix Marseille, FR
Ucb Biopharma Sprl, BE
Amgen Nv, BE
Boehriger Ingelheim International Gmbh, DE
Laboratorios Almirall S.A., ES
Netherlands Asthma Foundation, NL
Asthma Uk Lbg, GB
Merck Sharp And Dohme, Corp., US
International Primary Care Respiratory Group, GB
Lega Ltaliana Anti Fumo, IT
European Federation Of Asthma &Allergy Associations Ideell Forening, BE
Synairgen Research Ltd., GB
Biosci Consulting, BE
Janssen Biologics Bv, NL
Aerocrine Aktiebolag, SE
 
Title Journal Year Country Rel